Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Medtronic
Mallinckrodt
Chubb
Julphar
Federal Trade Commission
Farmers Insurance
McKinsey
Queensland Health
Fuji

Generated: October 23, 2017

DrugPatentWatch Database Preview

Ceftolozane sulfate; tazobactam sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ceftolozane sulfate; tazobactam sodium and what is the scope of ceftolozane sulfate; tazobactam sodium patent protection?

Ceftolozane sulfate; tazobactam sodium
is the generic ingredient in one branded drug marketed by Cubist Pharms Llc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ceftolozane sulfate; tazobactam sodium has forty-seven patent family members in twenty-six countries and seven supplementary protection certificates in six countries.

One supplier is listed for this compound.

Summary for Generic Name: ceftolozane sulfate; tazobactam sodium

US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list3,086
Drug Prices:see low prices
DailyMed Link:ceftolozane sulfate; tazobactam sodium at DailyMed

Pharmacology for Ingredient: ceftolozane sulfate; tazobactam sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ceftolozane sulfate; tazobactam sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,044,485Ceftolozane antibiotic compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ceftolozane sulfate; tazobactam sodium

Country Document Number Estimated Expiration
South Africa200504181► Subscribe
Japan2006506459► Subscribe
BrazilPI0315188► Subscribe
Australia2002952355► Subscribe
Australia2014233633► Subscribe
Japan2016517436► Subscribe
Taiwan200410977► Subscribe
Spain2290498► Subscribe
Australia2016200570► Subscribe
China1708502► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016Austria► SubscribePRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 (MITTEILUNG) 20150922
943Luxembourg► SubscribePRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
C0004France► SubscribePRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
0793Netherlands► SubscribePRODUCT NAME: CEFTOLOZAAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN IN HET BIJZONDER EEN ZWAVELZUURZOUT; REGISTRATION NO/DATE: EU/1/15/1032 20150922
2016 00004Denmark► SubscribePRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
2015000113Germany► SubscribePRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
2016 00004Denmark► SubscribePRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fuji
McKinsey
Harvard Business School
Covington
Novartis
QuintilesIMS
Deloitte
Baxter
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot